US 12,303,524 B2
Compositions comprising S-adenosylmethionine and a gallic acid ester
Dechi Guan, Vancouver (CA); and I. David MacDonald, Surrey (GB)
Assigned to MSI-195 HOLDINGS, LLC, Harrison, NY (US)
Filed by MSI-195 HOLDINGS, LLC, Harrison, NY (US)
Filed on Mar. 7, 2022, as Appl. No. 17/688,679.
Application 17/688,679 is a continuation of application No. 16/727,610, filed on Dec. 26, 2019, abandoned.
Application 16/727,610 is a continuation of application No. 15/932,359, filed on Feb. 16, 2018, abandoned.
Application 15/932,359 is a continuation of application No. 14/628,623, filed on Feb. 23, 2015, granted, now 9,925,208, issued on Mar. 27, 2018.
Application 14/628,623 is a continuation of application No. 14/247,061, filed on Apr. 7, 2014, granted, now 8,975,238, issued on Mar. 10, 2015.
Application 14/247,061 is a continuation of application No. PCT/CA2013/000876, filed on Oct. 16, 2013.
Claims priority of provisional application 61/715,138, filed on Oct. 17, 2012.
Prior Publication US 2022/0193107 A1, Jun. 23, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/7076 (2006.01); A61K 9/00 (2006.01); A61K 9/28 (2006.01); A61K 31/235 (2006.01); A61K 47/14 (2017.01); A61P 1/16 (2006.01); A61P 25/00 (2006.01); A61P 25/24 (2006.01); A61P 25/28 (2006.01); A61P 35/00 (2006.01); A61K 9/20 (2006.01); A61K 9/48 (2006.01)
CPC A61K 31/7076 (2013.01) [A61K 9/0053 (2013.01); A61K 9/28 (2013.01); A61K 31/235 (2013.01); A61K 47/14 (2013.01); A61P 1/16 (2018.01); A61P 25/00 (2018.01); A61P 25/24 (2018.01); A61P 25/28 (2018.01); A61P 35/00 (2018.01); A61K 9/2054 (2013.01); A61K 9/2059 (2013.01); A61K 9/4866 (2013.01)] 14 Claims
OG exemplary drawing
 
1. A method of treating a disease or disorder comprising administering a composition comprising an effective amount of exogenous S-adenosylmethionine (SAMe) and an effective amount of at least one gallic acid ester to a patient in need thereof,
wherein the composition is formulated as an oral dosage form,
wherein the disease or disorder is selected from the group consisting of depression, Alzheimer's disease, dementia, a liver disease or disorder, a cancer, an inflammatory disease or disorder, and atherosclerosis, and
wherein the at least one gallic acid ester is selected from the group consisting of methyl gallate, ethyl gallate, propyl gallate, butyl gallate, isobutyl gallate, amyl gallate, isoamyl gallate, hexyl gallate, isohexyl gallate, heptyl gallate, isoheptyl gallate, octyl gallate, and isooctyl gallate.